Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments

Company Overview - Akero Therapeutics (NASDAQ: AKRO) is actively developing its FGF21 drug efruxifermin, aimed at treating patients with compensated cirrhosis due to MASH and pre-cirrhotic MASH patients [2]. Product Development - The development of efruxifermin is a key focus for Akero Therapeutics, indicating strong progress in addressing significant medical needs within the liver disease space [2].